A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma.
A phase II study was undertaken to determine the efficacy of Bexarotene in melanoma. Between November 1997 and April 1998, 19 patients were given Bexarotene in single daily oral doses of 450 mg/m2 in capsule form continuously. Nineteen patients, four with choroidal metastatic melanoma, were treated. No responses were seen. Five patients had stable disease, two of the four with choroidal melanoma, had tumor progression. Myelosuppression was mild. Grade 3 myalgia, asthenia, diarrhea, cold hands/feet, and mood changes were seen in one patient each. Changes in serum triglyceride and thyroxine levels were common. Bexarotene, as used in this study, is not effective against melanoma.
Bedikian
A Y
AY
The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Plager
C
C
Papadopoulos
N
N
Ellerhorst
J
J
Smith
T
T
Benjamin
R S
RS
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077610:Bexarotene; D002214:Capsules; D002830:Choroid Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D002214:Capsules; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene